Liquidia Corporation

NasdaqCM LQDA

Liquidia Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -119.47 M

Liquidia Corporation Net Income is USD -119.47 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -104.55% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Liquidia Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -58.41 M, a -26.13% change year over year.
Liquidia Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -46.31 M, a -18.42% change year over year.
Liquidia Corporation Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -39.10 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	145
Sector	Health Care
Industries Pharmaceuticals

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Key trends

Past 5 years